

Appendix 1 (as supplied by authors): Drug plan formulary decisions based on 53 Common Drug Review recommendations

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
Ciclesonide	Alvesco	List	All provinces and NIHB (full listing)	None
nicotinic acid / lovastatin	Advicor	List	BC (full listing); QC (with criteria); NB (full listing); NS (full listing); PE (full listing); NL (full listing)	AB; SK; MB; ON; NIHB
drospirenone / ethinyl estradiol	Yasmin	List	BC (full listing); AB (full listing); SK (full listing); MB (full listing); ON (Full listing); QC (full listing); NB (full listing); NS (full listing); PE (full listing); NL (full listing); NIHB (full listing)	PE
eprosartan mesylate / hydrochlorothiazide	Teveten Plus	List in a similar manner	BC (with criteria); AB (full listing); SK (full listing); MB (full listing); ON (Full listing); QC (full listing); NB (full listing); NS (full listing); PE (full listing); NL (with criteria); NIHB (full listing)	None
insulin glulisine	Apidra	List in a similar manner	BC (full listing); AB (full listing); SK (with criteria); ON (with criteria); QC (full listing); NB (full listing); NS (with criteria); NL (with criteria); NIHB (full listing)	PE; MB

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
levodopa/ carbidopa/ entacapone	Stalevo	List in a similar manner	BC (with criteria); AB (full listing); SK (full listing); ON (with criteria); QC (full listing); NB (with criteria); NS (with criteria); NL (full listing); NIHB (full listing)	MB; PE
lanreotide acetate	Somatuline Autogel	List in a similar manner	AB (with criteria); SK (with criteria); ON (full listing); QC (full listing); NB (with criteria); NS (full listing); NL (full listing); NIHB (full listing)	BC; MB; PE
mycophenolate sodium	Myfortic	List in a similar manner	SK (with criteria); MB (with criteria); ON (full listing); QC (full listing); NB (full listing); PE (full listing); NIHB (with criteria)	BC; AB; NS; NL
acamprosate calcium	Campral	List with criteria	QC (with criteria); NB (with criteria); NS (with criteria); NIHB (with criteria)	BC; AB; SK; MB; ON; PE; NL
adalimumab	Humira	List with criteria	All provinces and NIHB (with criteria)	None
alglucosidase Alfa	Myozyme	List with criteria	SK (with criteria); ON (with criteria); QC (with criteria); NB (with criteria); NS (with criteria)	BC; AB; MB; PE; NL; NIHB
ambrisentan	Volibris	List with criteria	SK (with criteria); QC (with criteria); NB (with criteria); NS (with criteria); NL (with criteria)	BC; AB; MB; ON; PE; NIHB

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
amlodipine Besylate / atorvastatin Calcium	Caduet	List with criteria	SK (full listing); MB (with criteria); ON (with criteria); NB (with criteria); NS (full listing)	BC; AB; QC; PE; NL; NIHB
buprenorphine hydrochloride / naloxone hydrochloride dihydrate	Suboxone	List with criteria	AB (full listing); QC (with criteria); NB (with criteria); NS (with criteria)	BC; SK; MB; ON; PE; NL; NIHB
darifenacin Hydrobromide	Enablex	List with criteria	AB (with criteria); SK (with criteria); NB (with criteria); NS (with criteria); NL (with criteria); NIHB (with criteria)	BC; MB; ON; QC; PE
duloxetine hydrochloride	Cymbalta	List with criteria	AB (with criteria); SK (with criteria); ON (full listing); QC (with criteria); NB (with criteria); NS (with criteria); NIHB (with criteria)	BC; MB; PE; NL
entecavir	Baraclude	List with criteria	BC (with criteria); AB (with criteria); SK (with criteria); QC (with criteria); NB (with criteria); NS (with criteria); NL (with criteria); NIHB (with criteria)	MB; ON; PE
rivaroxaban	Xarelto	List with criteria	AB (with criteria); SK (with criteria); MB (with criteria); ON (with criteria); QC (with criteria); NB (with criteria); NS (with criteria); NL (with criteria)	BC; PE; NIHB

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
travoprost / timolol maleate	DuoTrav	List with criteria	BC (full listing); AB (full listing); SK (full listing); MB (full listing); ON (with criteria); QC (with criteria); NB (full listing); NS (full listing); PE (full listing); NL (full listing); NIHB (full listing)	None
tropium chloride	Trosec	List with criteria	AB (with criteria); SK (with criteria); MB (with criteria); QC (with criteria); NB (with criteria); NS (with criteria); PE (with criteria); NL (with criteria); NIHB (with criteria)	BC; ON
ziprasidone hydrochloride monohydrate	Zeldox	List with criteria	BC (with criteria); AB (full listing); SK (full listing); MB (full listing); QC (full listing); NB (with criteria); NS (with criteria); NL (with criteria); NIHB (with criteria)	ON; PE
deferasirox	Exjade	List with criteria	BC (with criteria); AB (with criteria); SK (with criteria); ON (with criteria); NB (with criteria); NS (with criteria)	MB; QC; PE; NL; NIHB
natalizumab	Tysabri	List with criteria	AB (with criteria); SK (with criteria); ON (with criteria); QC (with criteria)	BC; MB; NB; NS; PE; NL; NIHB

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
varenicline tartrate	Champix	List with criteria	QC (full listing); NIHB (with criteria)	BC; AB; SK; MB; ON; NB; NS; PE; NL
alefacept-Recombinant	Amevive	Do not list	None	All provinces and NIHB
alendronate sodium trihydrate / cholecalciferol	Fosavance	Do not list	ON (full listing)	BC; AB; SK; MB; QC; NB; NS; PE; NL; NIHB
aliskiren fumarate	Rasilez	Do not list	ON (with criteria); QC (with criteria)	BC; AB; SK; MB; NB; NS; NS; PE; NL; NIHB
ciclesonide	Omnaris	Do not list	ON (full listing)	BC; AB; SK; MB; QC; NB; NS; PE; NL; NIHB

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
cinacalcet hydrochloride	Sensipar	Do not list	QC (with criteria); NIHB (with criteria)	BC; AB; SK; MB; ON; NB; NS; PE; NL
dabigatran Etexilate Mesilate	Pradax	Do not list	None	All provinces and NIHB
daptomycin	Cubicin	Do not list	None	All provinces and NIHB
eletriptan hydrobromide	Relpax	Do not list	QC (full listing)	BC; AB; SK; MB; ON; NB; NS; PE; NL; NIHB
insulin aspart	NovoMix 30	Do not list	BC (full listing); ON (full listing); QC (with criteria)	AB; SK; MB; NB; NS; PE; NL; NIHB
lanthanum carbonate hydrate	Fosrenol	Do not list	QC (with criteria)	BC; AB; SK; MB; ON; NB; NS; PE; NL; NIHB

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
memantine hydrochloride	Ebixa	Do not list	QC (with criteria)	BC; AB; SK; MB; ON; NB; NS; PE; NL; NIHB
methylnaltrexone Bromide	Relistor	Do not list	None	All provinces and NIHB
omalizumab	Xolair	Do not list	None	All provinces and NIHB
paliperidone	Invega	Do not list	BC (full listing); ON (full listing)	AB; SK; MB; QC; NB; NS; PE; NL; NIHB
pegaptanib Sodium Salt	Macugen	Do not list	QC (with criteria)	BC; AB; SK; MB; ON; NB; NS; PE; NL; NIHB
pegvisomant	Somavert	Do not list	None	All provinces and NIHB
posaconazole	Posanol	Do not list	ON (with criteria); QC (with criteria)	BC; AB; SK; MB; NB; NS; PE; NL; NIHB

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
rasagiline Mesylate	Azilect	Do not list	ON (with criteria); QC (with criteria)	BC; AB; SK; MB; NB; NS; PE; NL; NIHB
rivastigmine	Exelon Patch	Do not list	BC (with criteria); QC (with criteria)	AB; SK; MB; ON; NB; NS; PE; NL; NIHB
sodium oxybate	Xyrem	Do not list	None	All provinces and NIHB
telbivudine	Sebivo	Do not list	None	All provinces and NIHB
tetrahydrocannabinol / cannabidiol	Sativex	Do not list	ON (with criteria)	BC; AB; SK; MB; QC; NB; NS; PE; NL; NIHB
tramadol hydrochloride	Zytram XL	Do not list	None	All provinces and NIHB
tramadol hydrochloride / acetaminophen	Tramacet	Do not list	None	All provinces and NIHB
atomoxetine hydrochloride	Strattera	Do not list	SK (with criteria); QC (with criteria)	BC; AB; MB; ON; NB; NS; PE; NL; NIHB

Generic name	Brand name	Common Drug Review recommendation	Drug plans with positive listing decision	Drug plans with negative listing decision
escalopram oxalate	Cipralext	Do not list	BC (full listing); ON (full listing)	AB; SK; MB; QC; NB; NS; PE; NL; NIHB
idursulfase	Elaprase	Do not list	ON (with criteria)	BC; AB; SK; MB; QC; NB; NS; PE; NL; NIHB
laronidase	Aldurazyme	Do not list	None	All provinces and NIHB
teriparatide	Forteo	Do not list	QC (with criteria)	BC; AB; SK; MB; ON; NB; NS; PE; NL; NIHB

Note: All Common Drug Review Recommendations are based off those made on or prior to May 27, 2009. All drug plan formulary decisions are based off the February 2010 version of IMS Brogan's FAME database.
Source: IMS Brogan, FAME database